Company Revenue

The company reported more than 35% growth in the first half of 2021 with gains driven by new products and...

The company improved in 2Q21 vs. last year but is dealing with regulatory and organization issues from the sale of...

The company benefitted from $41 million in one-time royalty and settlement payments in 2Q21 but its product revenue remains down...

The company's revenue grew double-digits in 2Q21 on the strength of share gains instead of recapturing backlogged procedures....

The company benefitted from improving COVID conditions in 2Q21 and remains on course to achieve both short and long-term strategic...

In 2Q21, the company grew modestly compared to the same period in 2019 due to newer products like the M-6...

The company outperformed expectations so far for 2021 and remains on track to realize growth in the 30% range for...

Despite continued momentum in its underlying growth trajectory for 2Q21, the company is taking a cautious approach to the balance...

In 2Q21 the company more than doubled its revenue from the second quarter of 2019, as adoption of its surgical...

The company continued its momentum in 2Q21 and made hefty investments to hit a targeted growth range of +30% to...